| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
389,580,000 |
| Market
Cap: |
43.08(B) |
| Last
Volume: |
4,690,332 |
Avg
Vol: |
1,930,532 |
| 52
Week Range: |
$75.49 - $140.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 487 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
71,005 |
274,979 |
309,595 |
581,627 |
| Total Sell Value |
$9,585,020 |
$36,298,507 |
$40,264,880 |
$70,726,419 |
| Total People Sold |
8 |
10 |
14 |
16 |
| Total Sell Transactions |
13 |
27 |
50 |
85 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
• – – |
2017-08-23 |
4 |
AS |
$75.26 |
$300,045 |
D/D |
(3,987) |
108,087 |
|
- |
|
| Ace Heather S |
SVP Human Resources |
• – – |
2017-08-23 |
4 |
D |
$75.33 |
$197,145 |
D/D |
(2,617) |
46,766 |
|
- |
|
| Sayer Kevin R |
President & CEO |
• • – |
2017-08-11 |
4 |
AS |
$69.77 |
$418,637 |
D/D |
(6,000) |
320,680 |
|
- |
|
| Balo Andrew K |
EVP, Reg. Strategy, Clinical |
• – – |
2017-08-10 |
4 |
AS |
$71.18 |
$230,921 |
D/D |
(3,244) |
99,989 |
|
- |
|
| Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
• – – |
2017-07-24 |
4 |
AS |
$69.47 |
$100,725 |
D/D |
(1,450) |
112,074 |
|
- |
|
| Sayer Kevin R |
President & CEO |
• • – |
2017-07-12 |
4 |
AS |
$71.86 |
$431,174 |
D/D |
(6,000) |
326,680 |
|
- |
|
| Balo Andrew K |
EVP, Reg. Strategy, Clinical |
• – – |
2017-07-10 |
4 |
AS |
$71.55 |
$228,972 |
D/D |
(3,200) |
103,233 |
|
- |
|
| Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
• – – |
2017-06-23 |
4 |
AS |
$78.19 |
$113,378 |
D/D |
(1,450) |
113,524 |
|
- |
|
| Doubleday Richard |
EVP, Chief Commercial Officer |
• – – |
2017-06-23 |
4 |
AS |
$78.22 |
$249,273 |
I/I |
(3,187) |
25,420 |
|
- |
|
| Sayer Kevin R |
President & CEO |
• • – |
2017-06-12 |
4 |
AS |
$69.07 |
$414,411 |
D/D |
(6,000) |
332,680 |
|
- |
|
| Balo Andrew K |
EVP, Clinical and Regulatory |
• – – |
2017-06-12 |
4 |
AS |
$69.06 |
$220,989 |
D/D |
(3,200) |
106,433 |
|
- |
|
| Augustinos Nicholas |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$4 |
D/D |
4,353 |
31,015 |
|
- |
|
| Skyler Jay S |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$5 |
D/D |
4,553 |
4,553 |
|
- |
|
| Kahn Barbara |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$4 |
D/D |
4,353 |
4,353 |
|
- |
|
| Altman Steven R |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$4 |
D/D |
4,353 |
4,353 |
|
- |
|
| Collins Richard Alexander |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$5 |
D/D |
5,355 |
5,855 |
|
- |
|
| Foletta Mark G |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$5 |
D/D |
4,952 |
20,595 |
|
- |
|
| Topol Eric |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$5 |
D/D |
4,653 |
4,653 |
|
- |
|
| Abbey Donald |
EVP Quality |
• – – |
2017-06-01 |
4 |
D |
$66.38 |
$516,707 |
D/D |
(7,784) |
74,726 |
|
- |
|
| Gregg Terrance H |
Executive Chairman |
• • – |
2017-05-24 |
4 |
OE |
$6.85 |
$205,500 |
D/D |
30,000 |
484,559 |
|
- |
|
| Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
• – – |
2017-05-23 |
4 |
AS |
$68.24 |
$98,949 |
D/D |
(1,450) |
114,974 |
|
- |
|
| Doubleday Richard |
EVP, Chief Commercial Officer |
• – – |
2017-05-23 |
4 |
AS |
$68.29 |
$217,290 |
I/I |
(3,182) |
28,607 |
|
- |
|
| Sayer Kevin R |
President & CEO |
• • – |
2017-05-17 |
4 |
AS |
$68.39 |
$591,525 |
D/D |
(8,649) |
338,680 |
|
- |
|
| Sayer Kevin R |
President & CEO |
• • – |
2017-05-17 |
4 |
OE |
$8.79 |
$32,075 |
D/D |
3,649 |
347,329 |
|
- |
|
| Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
• – – |
2017-05-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
116,424 |
|
- |
|
2309 Records found
|
|
Page 35 of 93 |
|
|
6.07 (5.2%) 
